212 related articles for article (PubMed ID: 33351090)
1. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.
de Vries S; Schaapveld M; Janus CPM; Daniëls LA; Petersen EJ; van der Maazen RWM; Zijlstra JM; Beijert M; Nijziel MR; Verschueren KMS; Kremer LCM; van Eggermond AM; Lugtenburg PJ; Krol ADG; Roesink JM; Plattel WJ; van Spronsen DJ; van Imhoff GW; de Boer JP; Aleman BMP; van Leeuwen FE
J Natl Cancer Inst; 2021 Jun; 113(6):760-769. PubMed ID: 33351090
[TBL] [Abstract][Full Text] [Related]
2. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.
Travis LB; Hill D; Dores GM; Gospodarowicz M; van Leeuwen FE; Holowaty E; Glimelius B; Andersson M; Pukkala E; Lynch CF; Pee D; Smith SA; Van't Veer MB; Joensuu T; Storm H; Stovall M; Boice JD; Gilbert E; Gail MH
J Natl Cancer Inst; 2005 Oct; 97(19):1428-37. PubMed ID: 16204692
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population.
Núñez-García B; Clemente MB; Sánchez JC; Royuela A; Ibargüen BCS; Méndez M; López-Ibor JV; Martínez M; Traseira C; Garitaonaindia Y; Aguado R; Calvo V; Torrente M; Parejo C; Provencio Z; Provencio M
Hematol Oncol; 2023 Aug; 41(3):407-414. PubMed ID: 36934306
[TBL] [Abstract][Full Text] [Related]
4. Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.
van Eggermond AM; Schaapveld M; Janus CP; de Boer JP; Krol AD; Zijlstra JM; van der Maazen RW; Kremer LC; van Leerdam ME; Louwman MW; Visser O; De Bruin ML; Aleman BM; van Leeuwen FE
Br J Cancer; 2017 Jul; 117(3):306-314. PubMed ID: 28632726
[TBL] [Abstract][Full Text] [Related]
5. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study.
Castellino SM; Geiger AM; Mertens AC; Leisenring WM; Tooze JA; Goodman P; Stovall M; Robison LL; Hudson MM
Blood; 2011 Feb; 117(6):1806-16. PubMed ID: 21037086
[TBL] [Abstract][Full Text] [Related]
6. Risk of male breast cancer after Hodgkin lymphoma.
de Vries S; Krul IM; Schaapveld M; Janus CPM; Rademakers SE; Roesink JM; Nijziel MR; Bilgin YM; Aleman BMP; van Leeuwen FE
Blood; 2023 Aug; 142(9):806-811. PubMed ID: 37390297
[TBL] [Abstract][Full Text] [Related]
7. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
Hisada M; Chen BE; Jaffe ES; Travis LB
J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
[TBL] [Abstract][Full Text] [Related]
8. Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis.
Ibrahim EM; Abouelkhair KM; Kazkaz GA; Elmasri OA; Al-Foheidi M
BMC Cancer; 2012 May; 12():197. PubMed ID: 22639888
[TBL] [Abstract][Full Text] [Related]
9. Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
Sud A; Thomsen H; Sundquist K; Houlston RS; Hemminki K
J Clin Oncol; 2017 May; 35(14):1584-1590. PubMed ID: 28384078
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.
Krul IM; Boekel NB; Kramer I; Janus CPM; Krol ADG; Nijziel MR; Zijlstra JM; van der Maazen RWM; Roesink JM; Jacobse JN; Schaapveld M; Schmidt MK; Opstal-van Winden AWJ; Sonke GS; Russell NS; Aleman BMP; van Leeuwen FE
Cancer; 2022 Dec; 128(24):4285-4295. PubMed ID: 36281718
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
Neppelenbroek SIM; Geurts YM; Aleman BMP; Lugtenburg PJ; Rademakers SE; de Weijer RJ; Schippers MGA; Ta BDP; Plattel WJ; Zijlstra JM; van der Maazen RWM; Nijziel MR; Ong F; Schimmel EC; Posthuma EFM; Kersten MJ; Böhmer LH; Muller K; Koene HR; Te Boome LCJ; Bilgin YM; de Jongh E; Janus CPM; van Leeuwen FE; Schaapveld M
J Clin Oncol; 2024 Jun; 42(16):1903-1913. PubMed ID: 38359378
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis.
Ibrahim EM; Kazkaz GA; Abouelkhair KM; Al-Mansour MM; Al-Fayea TM; Al-Foheidi M; Bayer AM; Elmasri OA
Lung; 2013 Feb; 191(1):117-34. PubMed ID: 23053567
[TBL] [Abstract][Full Text] [Related]
13. Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group.
Holmqvist AS; Chen Y; Berano Teh J; Sun C; Birch JM; van den Bos C; Diller LR; Dilley K; Ginsberg J; Martin LT; Nagarajan R; Nathan PC; Neglia JP; Terenziani M; Tishler D; Meadows AT; Robison LL; Oberlin O; Bhatia S
Cancer; 2019 Apr; 125(8):1373-1383. PubMed ID: 30556153
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks.
Yeh JM; Diller L
Blood; 2012 Sep; 120(11):2195-202. PubMed ID: 22826564
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.
De Bruin ML; Sparidans J; van't Veer MB; Noordijk EM; Louwman MW; Zijlstra JM; van den Berg H; Russell NS; Broeks A; Baaijens MH; Aleman BM; van Leeuwen FE
J Clin Oncol; 2009 Sep; 27(26):4239-46. PubMed ID: 19667275
[TBL] [Abstract][Full Text] [Related]
16. Reduced Mortality Risk in the Recent Era in Early-Stage Hodgkin Lymphoma Patients Treated With Radiation Therapy With or Without Chemotherapy.
Patel CG; Michaelson E; Chen YH; Silver B; Marcus KJ; Stevenson MA; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):498-506. PubMed ID: 29153331
[TBL] [Abstract][Full Text] [Related]
17. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.
Schaapveld M; Aleman BM; van Eggermond AM; Janus CP; Krol AD; van der Maazen RW; Roesink J; Raemaekers JM; de Boer JP; Zijlstra JM; van Imhoff GW; Petersen EJ; Poortmans PM; Beijert M; Lybeert ML; Mulder I; Visser O; Louwman MW; Krul IM; Lugtenburg PJ; van Leeuwen FE
N Engl J Med; 2015 Dec; 373(26):2499-511. PubMed ID: 26699166
[TBL] [Abstract][Full Text] [Related]
18. Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: report of the Childhood/Adolescent/Young Adult Cancer Survivors Research Program and the BC Cancer Agency Centre for Lymphoid Cancer.
Bhuller KS; Zhang Y; Li D; Sehn LH; Goddard K; McBride ML; Rogers PC
Br J Haematol; 2016 Mar; 172(5):757-68. PubMed ID: 26727959
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study.
Elkin EB; Klem ML; Gonzales AM; Ishill NM; Hodgson D; Ng AK; Marks LB; Weidhaas J; Freedman GM; Miller RC; Constine LS; Myrehaug S; Yahalom J
J Clin Oncol; 2011 Jun; 29(18):2466-73. PubMed ID: 21576642
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.
van Nimwegen FA; Schaapveld M; Janus CP; Krol AD; Petersen EJ; Raemaekers JM; Kok WE; Aleman BM; van Leeuwen FE
JAMA Intern Med; 2015 Jun; 175(6):1007-17. PubMed ID: 25915855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
